KIT and gastrointestinal stromal tumor: As mentioned before, despite the initial clinical benefits of IM-based targeted therapy, most GIST patients develop IM resistance over two years due to secondary resistance mutations in KIT, thus suggesting that this time period is critical for the genetic changes responsible for secondary IM resistance in vivo.